Microsoft word - cattle - mos to milk replacer for dairy calves.doc
EXAMINATION OF THE ADDITION OF YEAST CELL WALL
MATERIAL (MOS) TO MILK REPLACER FOR DAIRY CALVES.
Introduction: Prebiotic fiber inclusion in animal diets has been studied as to impact on gut health and subsequent animal performance. A variety of oligosaccharides are available, and several researchers have reported on the benefits of mannanoligosaccharides (MOS) when added to the milk replacer of dairy calves. A common source of mannanoligosaccharides is the cell wall of yeast (Saccharomyces cerevisiae). IMMUNOWALLTM is such a yeast cell wall product and contains mannanoligosaccharides (14-20%) and β glucans (22-28%). A MOS source that is used in calf programs is other one and the guarantee reads 25% minimum glucomannanoprotein. Objective: The objective of this study was to evaluate the effect of IMMUNOWALLTM addition to calf milk replacer. Research Method: The trial was contracted with a Midwestern feed company and begun in August of 2006. Calves were acquired from a single dairy farm after they had access to colostrum. They were housed in individual hutches. A total of 39 heifer calves were randomly assigned to one of 3 milk replacer treatments (13 calves per treatment):
Treatment 1 – Control: standard all milk formula (20% CP; 20% CF) with NT (333g
Treatment 2 – MOS 1: standard all milk formula with NT and MOS 1 to provide 4g/calf/day. Treatment 3 - IMMUNOWALLTM: standard all milk formula with NT and IMMUNOWALLTM to
A common 18% CP calf starter was provided to all calves. It was a texturized feed containing a mix of cracked & whole grains, pellets and molasses. It was medicated with dequinate at the prescribed level. Milk replacer powder and water were accurately weighed and fed two times per day. Calves were weaned by offering 1 feeding per day of milk replacer during days 36-42. Fresh calf starter was offered daily starting at day four. Unconsumed starter was composited on a daily basis and weighed weekly to determine actual intake for the week. Calves were weighed every 7 days. The trial period was 8 weeks.
ICC Industrial Comércio Exportação e Importação Ltda.
Av. Brigadeiro Faria Lima 1768 cj. 4C Jardim Paulistano 01451-909 São Paulo SP Brazil
Phone:+55 11 3093 0799 Fax:+55 11 3816 7661 icc@iccbrazil.com.br www.yeastbrazil.com
Results: Calf health was very good throughout the trial. Consequently neither calf scours nor respiratory illness was a problem. Calves on Treatment 3 (IMMUNOWALLTM) had significantly greater weight gains (6 weeks) and calf starter intakes (6 weeks, 8 weeks and total) than calves on Treatment 2 (MOS 1). The performance of the Treatment 1 calves (Control) was not significantly different than either of the two MOS treatments but was numerically better than the MOS 1 group. The MOS 1 group had the poorest performance of the three groups in this study. From the results of this study IMMUNOWALLTM appears to be reliable MOS source for use in calf milk replacer formulations. Calf performance when receiving milk replacer with alternatives sources of MOS.
a,b Means in a row without common superscripts differ (P≤0.10).
Advantages to Adding IMMUNOWALLTM TO Milk Replacers
Benefit – Reduction in the incidence of diarrhea, scours or enteritis.
Benefit – Improved gut integrity to promote more efficient feed absorption.
Benefit – Increased titer levels to vaccines
Benefit – Reduced incidence of respiratory disease.
ICC Industrial Comércio Exportação e Importação Ltda.
Av. Brigadeiro Faria Lima 1768 cj. 4C Jardim Paulistano 01451-909 São Paulo SP Brazil
Phone:+55 11 3093 0799 Fax:+55 11 3816 7661 icc@iccbrazil.com.br www.yeastbrazil.com
IMMUNOWALLTM improvement on the calf’s Average Daily Gain (ADG) in pounds (6 weeks and 8 weeks).
IMMUNOWALLTM reduces the producers feed cost per pound gained, which in turn will increase profits.
* The trial was contracted with a Midwestern feed company and begun in August of 2006. Calves were acquired from a single dairy farm after they had access to colostrum. They were housed in individual hutches.
ICC Industrial Comércio Exportação e Importação Ltda.
Av. Brigadeiro Faria Lima 1768 cj. 4C Jardim Paulistano 01451-909 São Paulo SP Brazil
Phone:+55 11 3093 0799 Fax:+55 11 3816 7661 icc@iccbrazil.com.br www.yeastbrazil.com
FDA Okays Another Once-Daily HIV Pill By Joyce Frieden, News Editor, MedPage Today Reviewed by August 10, 2011 WASHINGTON -- The FDA has approved a second once-daily tablet for HIV -- this one combining three medications: emtricitabine, rilpivirine, and tenofovir. The pill, manufactured by Gilead Sciences, combines that company's Truvada -- itself a combination of the two nucleosid
T h e n e w e ng l a n d j o u r na l o f m e dic i n eProphylactic Fluconazole in Preterm NeonatesPaolo Manzoni, M.D., Ilaria Stolfi, M.D., Lorenza Pugni, M.D., Lidia Decembrino, M.D., Cristiana Magnani, M.D., Gennaro Vetrano, M.D., Elisabetta Tridapalli, M.D., Giuseppina Corona, M.D., Chiara Giovannozzi, M.D., Daniele Farina, M.D., Riccardo Arisio, M.D., Franco Merletti, M.D., Ph.D., M